New combo therapy targets resistant prostate cancer

NCT ID NCT05177042

Completed Disease control Sponsor: Arvinas Androgen Receptor, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a new drug, ARV-110, combined with the standard treatment abiraterone in 45 men with metastatic prostate cancer whose PSA levels were rising despite abiraterone alone. The main goals were to check safety and find the best dose. The study is complete, but results are not yet available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER METASTATIC

Contacts and locations

Locations

Clinical Trial Site

Santa Monica, California, 91361, United States
Clinical Trial Site

New Haven, Connecticut, 06519, United States
Clinical Trial Site

Fort Myers, Florida, 33916, United States
Clinical Trial Site

Boston, Massachusetts, 02114, United States
Clinical Trial Site

Columbus, Ohio, 43210, United States
Clinical Trial Site

Portland, Oregon, 97239, United States
Clinical Trial Site

Myrtle Beach, South Carolina, 29572, United States
Clinical Trial Site

Nashville, Tennessee, 37203, United States
Clinical Trial Site

Charlottesville, Virginia, 22903, United States
Clinical Trial Site

Vancouver, British Columbia, Canada
Clinical Trial Site

Toronto, Ontario, Canada
Clinical Trial Site

Montreal, Quebec, Canada
Clinical Trial Site

Caen, France
Clinical Trial Site

Paris, France
Clinical Trial Site

Villejuif, France
Clinical Trial Site

London, England, United Kingdom
Clinical Trial Site

Cardiff, Wales, United Kingdom
Clinical Trial Site

Preston, PR2 9HT, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.